Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;26(9):2156-2165.
doi: 10.1007/s12094-024-03478-5. Epub 2024 Apr 10.

The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review

Affiliations
Review

The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review

Wenxin Da et al. Clin Transl Oncol. 2024 Sep.

Abstract

Indeed, tumors are a significant health concern worldwide, and understanding the underlying mechanisms of tumor development is crucial for effective prevention and treatment. Epigenetics, which refers to changes in gene expression that are not caused by alterations in the DNA sequence itself, plays a critical role in the entire process of tumor development. It goes without saying that the effect of methylation on tumors is a significant aspect of epigenetics. Among the methylation modifications, DNA methylation is an important part, which plays a regulatory role in tumor-related genes. Ten-eleven translocation 2 (TET2) is a highly influential protein involved in the modification of DNA methylation. Its primary role is associated with the suppression of tumor development, making it a significant player in cancer research. However, TET2 is frequently mentioned in hematological diseases, its role in solid tumors has received little attention. Studying the changes of TET2 in solid tumors and the regulatory mechanism will facilitate its investigation as a clinical target for targeted therapy and may also provide directions for clinical treatment of malignant tumors.

Keywords: DNA methylation; Epigenetic; Solid tumors; TET2.

PubMed Disclaimer

Similar articles

References

    1. Pan Y, Liu G, Zhou F, Su B, Li Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 2018;18:1–14. https://doi.org/10.1007/s10238-017-0467-0 . - DOI - PubMed
    1. Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19:145. https://doi.org/10.1186/s12943-020-01258-7 . - DOI - PubMed - PMC
    1. Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer. 2020;6:580–92. https://doi.org/10.1016/j.trecan.2020.02.003 . - DOI - PubMed - PMC
    1. Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi Y, et al. DNA methylation, its mediators and genome integrity. Int J Biol Sci. 2015;11:604–17. https://doi.org/10.7150/ijbs.11218 . - DOI - PubMed - PMC
    1. Dai X, Ren T, Zhang Y, Nan N. Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med. 2021;23:e2. https://doi.org/10.1017/erm.2021.4 . - DOI - PubMed - PMC

LinkOut - more resources